In patients with advanced pancreatic cancer that no longer responds to standard chemotherapy, a new RAS inhibitor increases survival time compared to standard chemotherapy.
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
In patients with advanced pancreatic cancer that no longer responds to standard chemotherapy, a new RAS inhibitor increases survival time compared to standard chemotherapy.
See the technical phrasing
A novel RAS inhibitor significantly extends survival in patients with chemotherapy-refractory metastatic pancreatic cancer compared to standard chemotherapy.
A drug binds to the active form of a mutated protein called RAS, stopping it from sending growth signals to cancer cells. This causes the cancer cells to stop multiplying and die, shrinking the tumor and slowing its spread, which allows patients to live longer.
What the research says
Supports
2 studies
Study: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 2 supporting studies